行情

AMGN

AMGN

安进
NASDAQ

实时行情|Nasdaq Last Sale

220.57
-2.39
-1.07%
交易中 14:14 02/20 EST
开盘
223.20
昨收
222.96
最高
223.48
最低
218.52
成交量
75.32万
成交额
--
52周最高
244.99
52周最低
166.30
市值
1,300.94亿
市盈率(TTM)
17.13
分时
5日
1月
3月
1年
5年

分析师评级

26位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AMGN 新闻

  • Nations largest insurer invests in Waltham healthcare AI startup
  • American City Business Journals.2小时前
  • Would you tell secrets to Alexa or Siri? How AI therapists could save you time and money on mental health care
  • MarketWatch.1天前
  • Revolution Medicines Joins Amgen and Mirati in Quest for New Type of Cancer Drugs
  • GuruFocus.com.1天前
  • Amgen Stock: Is It Time To Buy This Biotech After Its Failed Breakout?
  • Investor's Business Daily.1天前

更多

所属板块

制药
-0.67%
制药与医学研究
-0.57%

热门股票

名称
价格
涨跌幅

AMGN 简况

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
展开

Webull提供Amgen, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。